Mochida Pharmaceutical Co., Ltd.

Sankyo Company, Limited

Other

Otsuka Pharmaceutical Company, Limited

Sumitomo Chemical Company, Limited

Takeda Pharmaceutical Company Limited

Ono Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Mochida Pharmaceutical., Ltd.

Shimomura, Iichiro

Funahashi, Tohru

Matsuzawa, Yuji

Yuji Matsuzawa

Masako Nishizawa

Hiroko Murakami

Yasushi Saito

Masunori Matsuzaki

Hideki Origasa

Mitsuhiro Yokoyama

Tohru Funahashi

Shinichi Oikawa

Shinji Tamura

Yuichi Ishikawa

Toru Kita

Hiroshige Itakura

Yasukazu Ohmoto

Iichiro Shimomura

Noriaki Nakaya

Toshiie Sakata

Kazuyuki Shimada

Kunio Shirato

Jun Sasaki

Hitoshi Hishida

Akira Kitabatake

Masahiko Ohta

Paul W Kincade

Makoto Makishima

Naoki Furuyama

Iichirou Shimomura

Toshiyuki Takagi

Masanori Iwaki

Yoshiaki Tomiyama

Kenji Oritani

Masanori c/o Ono Pharmaceutical Co Ltd Iwaki

Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.

Composition for preventing the occurrence of cardiovascular event in multiple risk patient

A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.

Composition for reducing new-onset diabetes

The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.

Adiponectin production enhancer

By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.

Composition and/or method for preventing recurrence of stroke

Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.

Composition and/or method for preventing onset and/or recurrence of cardiovascular events

The present invention provides a new anti-tumor agent containing adiponectin as an active ingredient, particularly, an anti-tumor agent capable of inhibiting carcinogenesis in the liver, use of adiponectin as an anti-tumor agent, and a prophylactic or therapeutic method against a tumor using adiponectin. The administration form may be either oral administration, e.g., by tablets or parenteral administration, e.g., by injection; in the case of intravenous injection for inhibiting carcinogenesis in the liver, the dosage is 1 to 100 mg/kg/day per adult patient.

Anti-tumor agent

A method of suppressing the differentiation of an adipocite and/or lipid accumulation in an adipocyte, which comprises contacting the adipocyte with a protein comprising the amino acid sequence of SEQ ID NO: 2 or a salt thereof, or with a polynucleotide comprising a sense strand sequence encoding a protein comprising the amino acid sequence of SEQ ID NO: 2.

Proteins and use thereof

The present invention relates to a DNA having a promoter region containing regulatory sequences of human adiponectin gene, transformants transformed with the DNA, a screening method of a compound which can enhance the human adiponectin promoter activity, which the transformants are used, and the screening kit, and a screening method of a preventive/therapeutic medicine for syndromes such as Syndrome X, metabolic syndrome, multiple risk factor syndrome, insulin resistant syndrome, deadly quartet, and visceral fat syndrome, metabolic disorders such as diabetes, obesity, hypercholesterolemia, and hyperlipoproteinemias, hyperlipidemia, arteriosclerosis, hypertonia, circulatory system disease, and hyperphagia and a pharmaceutical composition obtained by using them.

Adiponectin promoter and use thereof

Composition and method for preventing recurrence of stroke

Growing community of inventors

Takarazuka, Japan

Yuji Matsuzawa